Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Editas Medicine, Inc. < Previous 1 2 Next > Editas Medicine to Participate in Upcoming Investor Conferences November 06, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Third Quarter 2024 Results and Business Updates November 04, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update October 22, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics October 21, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept October 18, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust October 03, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Participate in Upcoming Investor Conferences August 28, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Second Quarter 2024 Results and Business Updates August 07, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update July 31, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress June 14, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress June 14, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June May 14, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting May 10, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces First Quarter 2024 Results and Business Updates May 08, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events May 02, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration May 01, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers BMY EDIT Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting April 22, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates February 28, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events February 21, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Participate in Upcoming Investor Conferences January 31, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference January 08, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 December 13, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar December 11, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Third Quarter 2023 Results and Business Updates November 03, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar November 02, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events October 27, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease October 16, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer September 25, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer September 25, 2023 From Editas Medicine, Inc. Via GlobeNewswire Tickers EDIT < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
